Počet záznamov: 1
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
- Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE' / Šufliarsky J. ... [et al.]. Onkológia Roč. 13, č. 3 (2018), s. 222
článok
Počet záznamov: 1